The north and south of Candidemia: Issues for Latin America

Drugs of Today

Volumn 44, Issue SUPPL. A, 2008, Pages 1-34

  Colombo, Arnaldo Lopes ^a   Thompson, Luis ^b   Graybill, John R ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

^c University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ALGORITHM; ANTIFUNGAL ACTIVITY; ARACHNOIDITIS; AREA UNDER THE CURVE; BLOOD CULTURE; BOVINE DIARRHEA VIRUS; BRAZIL; CANADA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; DRUG CHOICE; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; KIDNEY FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHLEBITIS; PREGNANCY; PREVALENCE; REVIEW; RISK FACTOR; SOUTH AND CENTRAL AMERICA; SPECIES DISTRIBUTION; SPECIES IDENTIFICATION; THERAPY DELAY; TREATMENT PLANNING; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDIASIS; FEMALE; HUMANS; INCIDENCE; LATIN AMERICA; MALE; UNITED STATES;

EID: 56049113250     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. Eggimann, P., Garbino, J., Pittet, D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3(11): 685-702.
2. Pfaller, M.A., Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007, 20(1): 133-63.
3. Hajjeh, R.A., Sofair, A.N., Harrison, L.H. et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a populationbased active surveillance program. J Clin Microbiol 2004, 42(4): 1519-27.
4. Tortorano, A.M., Peman, J., Bernhardt, H. et al.; ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23(4): 317-22.
5. Nucci, M., Anaissie, E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001,3(12): 1959-67.
6. Samonis, G., Gikas, A., Anaissie, E.J., Vrenzos, G., Maraki, S., Tselentis, Y., Bodey, G.P. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993, 37(1): 51-3.
7. Walsh, T.J., Hiemenz, J., Pizzo, P.A. Evolving risk factors for invasive fungal infections-all neutropenic patients are not the same. Clin Infect Dis 1994, 18(5): 793-8.
8. Anaissie, E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992, 14(Suppl 1): S43-53.
9. Rex, J.H., Bennett, J.E., Sugar, A.M., Pappas, P.G., Serody, J., Edwards, J.E., Washburn, R.G. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995, 21(4): 994-6.
10. Morgan, J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005, 7(6): 429-39.
11. Wingard, U.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20(1): 115-25.
12. Wingard, J.R., Merz, W.G., Rinaldi, M.G., Miller, C.B., Karp, J.E., Saral, R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37(9): 1847-9.
13. Ostrosky-Zeichner, L., Rex, J.H., Pappas, P.G. et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47(10): 3149-54.
14. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J., Edwards, J.E.; Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, (2): 161-89.
15. Pappas, P.G., Rex, J.H., Lee, J. et al.; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, (5): 634-43.
16. Baillie, G.S., Douglas, L.J. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol 1999, 10: 644-56.
17. Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T., Ghannoum, M.A. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001, 183(18): 5385-94.
18. Kuhn, D.M., George, T., Chandra, J., Mukherjee, P.K., Ghannoum, M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002, 46(6): 1773-80.
19. Mukherjee, P.K., Chandra, J., Kuhn, D.M,, Ghannoum, M.A. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003, 71(8): 4333-40.
20. López-Ribot, J.L. Candida albicans biofilms: More than filamentation. Curr Biol 2005, 15(12): R453-5.
21. Solomon, S.L., Khabbaz, R.F., Parker, R.H., Anderson, R.L., Geraghty, M.A., Furman, R.M., Marione, W.J. An outbreak of Candida parapsilosis blood stream infections in patients receiving parenteral nutrition. J Infect Dis 1984, 149(1): 98-102.
22. Weems, J.J. Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992, 14(3): 756-66.
23. Colombo, A.L., Nucci, M., Park, B.J. et al.; Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006, 44(8): 2816-23.
24. da Matta, D.A., de Almeida, L.P., Machado, A.M. et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: Results of a multicenter study conducted in São Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis 2007, 57(4): 399-404.
25. Colombo, A.L., Guimarães, T., Silva, L.R. et al. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007, 28(5): 570-6.
26. Paganini, H., Rodriguez Brieshcke, T., Santos, P., Seú, S., Rosanova, M.T. Risk factors for nosocomial candidaemia: A case-control study in children. J Hosp Infect 2002, 50(4): 304-8.
27. Banerjee, S.N., Emori, T.G., Culver, D.H. et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991, 91(3B): 86S-89S.
28. Macphail, G.L., Taylor, G.D., Buchanan-Chell, M., Ross, C., Wilson, S., Kureishi, A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002, 45(5-6): 141-5.
29. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3): 309-17.
30. Jarvis, W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20(6): 1526-30.
31. 31.Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R.F., Wenzel, R.P. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148(12): 2642-5.
32. Rittet, D., Wenzel, R.P. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155(11): 1177-84.
33. Kao, A.S., Brandt, M.E., Pruitt, W.R. et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999, 29(5): 1164-70.
34. Viscoli, C., Castagnola, E., Giacchino, M. et al. Bloodstream infections in children with cancer: A multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 1999, 35(5): 770-4.
35. Colombo, A.L., Guimarães, T. [Epidemiology of hematogenous infections due to Candida spp]. Rev Soc Bras Med Trop 2003, 36(5): 599-607.
36. Pfaller, M.A., Diekema, D.J.; International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10 Suppi 1: 11-23.
37. Colombo, A.L., Nucci, M., Salomão, R., Branchini, M.L., Richtmann, R., Derossi, A., Wey, S.B. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999, 34(4): 281-6.
38. Antunes, A.G., Pasqualotto, A.C., Diaz, M.C., d'Azevedo, P.A., Severe, L.C. Candidemia in a Brazilian tertiary care hospital: Species distribution and antifungal susceptibility patterns. Rev Inst Med Trop Sao Paulo 2004, 46(5): 239-41.
39. Aquino, V.R., Lunardi, L.W., Goldani, L.Z., Barth, A.L. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis 2005, 9(5): 411-8.
40. Rodero, L., Davel, G., Soria, M., Vivot, W., Córdoba, S., Canteros, C.E., Saporiti, A.; EMIFN. [Multicenter study of fungemia due to yeasts in Argentina]. Rev Argent Microbiol 2005, 37(4): 189-95.
41. Silva, V., Díazm, M.C., Febré, N.; Chilean Invasive Fungal Infections Group. Invasive fungal infections in Chile: A multicenter study of fungal prevalence and susceptibility during a 1-year period. Med Mycol 2004, 42(4): 333-9.
42. Cortes, J.A., Leal, A.L., Buitrago, G., Castillo, J.S. Fungal bloodstream infections in a citywide network in Bogota, Colombia, 2001-2006. Clin Microbiol Infect 2008, 14(Suppl 7): S455.
43. Pfaller, M.A., Diekema, D.J., Jones, R.N., Messer, S.A., Mollis, R.J.; SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002, 40(3): 852-6.
44. Sandven, P. Epidemiology of candidemia. Rev Iberoam Micol 2000, 17(3): 73-81.
45. Colombo, A.L., Perfect, J., DiNubile, M. et al. Global distribution and outcomes for Candida species causing invasive candidiasis: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003, 22(8): 470-4.
46. Pfaller, M.A., Diekema, D.J., Gibbs, D.L. et al.; Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007, 45(6): 1735-45.
47. Diekema, D.J., Messer, S.A., Brueggemann, A.B., Coffman, S.L., Doern, G.V., Herwaldt, L.A., Pfaller, M.A. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40(4): 1298-302.
48. Rodero, L., Davel, G., Córdoba, S., Soria, M., Canteros, C., Hochenfellner, F. [Multicenter study on nosocomial candidiasis in the Republic of Argentina]. Rev Argent Microbiol 1999, 31(3): 114-9.
49. Cuenca-Estrella, M., Rodero, L., García-Effrón, G., Rodriguez-Tudela, J.L. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2002, 49(6): 981-7.
50. Pfaller, M.A., Jones, R.N., Doern, G.V., Sader, H.S., Mollis, R.J., Messer, S.A. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998, 36(7): 1886-9.
51. Pfaller, M.A., Diekema, D.J., Gibbs, D.L. et al.; Global Antifungal Surveillance Group. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: A global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 46(3): 842-9.
52. Garey, K.W., Rege, M., Pai, M.P., Mingo, D.E., Suda, K.J., Turpin, R.S., Bearden, D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43(1): 25-31.
53. Morrell, M., Fraser, V.J., Kollef, M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49(9): 3640-5.
54. Dignani, M.C., Solomkin, J.S., Anaissie, E.J. Candida. In: Anaissie, E.J., McGinnis, M.R., Pfaller, M.A. (Eds.). Clinical Mycology. Churchill Living-stone: New York 2003, 195-239.
55. Pappas, P.G. Invasive candidiasis. Infect Dis Clin North Am 2006, 20(3): 485-506.
56. Kauffman, C.A., Bradley, S.F., Ross, S.C., Weber, D.R. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991, 91(2): 137-41.
57. Thaler, M., Pastakia, B., Shawker, T.H., O'Leary, T., Pizzo, P.A. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 1988, 108(1): 88-100.
58. Alexander, B.D., Pfaller, M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006, 43(s1): S15-27.
59. Ellepola, A.N., Morrison, C.J. Laboratory diagnosis of invasive candidiasis. J Microbiol 2005, 43 Spec No: 65-84.
60. Reimer, L.G., Wilson, M.L., Weinstein, M.P. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997, 10(3): 444-65.
61. Horvath, L.L., George, B.J., Murray, C.K., Harrison, L.S., Hospenthal, D.R. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol 2004, 42(1): 115-8.
62. Bouza, E., Sousa, D., Rodríguez-Créixems, M., Lechuz, J.G., Muñoz, P. Is the volume of blood cultured still a significant factor in the diagnosis of bloodstream infections? J Clin Microbiol 2007, 45(9): 2765-9.
63. Lamy, B., Roy, P., Garret, G., Flandrois, J.P., Delignette-Muller, M.L. What is the relevance of obtaining multiple blood samples for culture? A comprehensive model to optimize the strategy for diagnosing bacteremia. Clin Infect Dis 2002, 35(7): 842-50.
64. Krcmery, V., Barnes, A.J. Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect 2002, 50(4): 243-60.
65. Wilson, D.A., Joyce, M.J., Hall, L.S. et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005, 43(6): 2909-12.
66. Pincus, D.H., Orenga, S., Chatellier, S. Yeast identification-past, present, and future methods. Med Mycol 2007, 45(2): 97-121.
67. Pincus, D.H., Coleman, D.C., Pruitt, W.R. et al. Rapid identification of Candida dubliniensis with commercial yeast identification systems. J Clin Microbiol 1999, 37(11): 3533-9.
68. Kurzai, O., Heinz, W.J., Sullivan, D.J., Coleman, D.C., Frosch, M., Mühlschlegel, F.A. Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated PHR1 and PHR2 genes of C. albicans. J Clin Microbiol 1999, 37(5): 1587-90.
69. Park, S., Wong, M., Marras, S.A. et al. Rapid identification of Candida dubliniensis using a species-specific molecular beacon. J Clin Microbiol 2000, 38(8): 2829-36.
70. Tavanti, A., Davidson, A.D., Gow, N.A., Maiden, M.C., Odds, FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43(1): 284-92.
71. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard M27-A2. 2nd Ed. CLSI: Wayne, PA 2002.
72. Cuenca-Estrella, M., Díaz-Guerra, T.M., Mellado, E., Rodríguez-Tudela, J.L. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001, 39(2): 525-32.
73. Clinical and Laboratory Standards Institute. Reference method for antifungal disk diffusion susceptibility testing of yeasts: Approved guideline M44-A. CLSI: Wayne, PA 2004.
74. Colombo, A.L., Barchiesi, F., McGough, D.A., Rinaldi, M.G. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995, 33(3): 535-40.
75. Pfaller, M.A., Espinel-Ingroff, A., Jones, R.N. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 2004, 42(10): 4577-80.
76. Matar, M.J., Ostrosky-Zeichner, L., Paetznick, V.L., Rodriguez, J.R., Chen, E., Rex, J.H. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003, 47(5): 1647-51.
77. Pfaller, M.A., Diekema, D.J., Sheehan, DJ. Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006, 19(2): 435-47.
78. Nguyen, M.H., Clancy, C.J., Yu, V.L. et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998, 177(2): 425-30.
79. Park, B.J., Arthington-Skaggs, B.A., Hajjeh, R.A. et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006, 50(4): 1287-92.
80. Kartsonis, N., Killar, J., Mixson, L., Hoe, C.M., Sable, C., Bartizal, K., Motyl, M. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005, 49(9): 3616-23.
81. Pfaller, M.A., Diekema, D.J. Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40(10): 3551-7.
82. Forrest, G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006, 19(6): 538-43.
83. Rex, J.H., Pfaller, M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002, 35(8): 982-9.
84. Gallis, H.A., Drew, R.H., Pickard, W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12(2): 308-29.
85. Drutz, D.U., Spickard, A., Rogers, D.E., Koenig, M.G. Treatment of disseminated mycotic infections. A new approach to amphotericin B therapy. Am J Med 1968, 45(3): 405-18.
86. Wingard, J.R., Kubilis, P., Lee, L. et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999, 29(6): 1402-7.
87. Kanafani, Z.A., Perfect, U.R. Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact. Clin Infect Dis 2008, 46(1): 120-8.
88. Dick, J.D., Merz, W.G., Saral, R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980, 18(1): 158-63.
89. Sokol-Anderson, M.L., Brajtburg, J., Medoff, G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986, 154(1): 76-83.
90. Bates, D.W., Su, L., Yu, D.T. et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32(5): 686-93.
91. Harbarth, S., Burke, J.P., Lloyd, J.F., Evans, R.S., Pestotnik, S.L., Samore, M.H. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002, 35(12): e120-7.
92. Zaoutis, T.E., Argon, J., Chu, J., Berlin, J.A., Walsh, T.J., Feudtner, C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41(9): 1232-9.
93. Ostrosky-Zeichner, L., Marr, K.A., Rex, J.H., Cohen, S.H. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003, 37(3): 415-25.
94. White, M.H., Bowden, R.A., Sandler, E.S. et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27(2): 296-302.
95. White, M.H., Anaissie, E.J., Kusne, S. et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997, 24(4): 635-42.
96. Graybill, J.R. Lipid formulations for amphotericin B: Does the emperor need new clothes? Ann Intern Med 1996, 124(10): 921-3.
97. Wingard, J.R., White, M.H., Anaissie, E., Raffalli, J., Goodman, J., Arrieta, A; L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000, 31(5): 1155-63.
98. Drutz, D.J. Rapid infusion of amphotericin B: Is it safe, effective, and wise? Am J Med 1992, 93(2): 119-21.
99. Imhof, A., Walter, R.B., Schaffner, A. Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study. Clin Infect Dis 2003, 36(8): 943-51.
100. Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D.W., Lortholary, O. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006, 57(3): 384-410.
101. Antignac, E., Fakuhara, M., Kimura, M., Ushio, F. Clotrimazole-induced modulation of hepatic cytochrome P450 enzymes in Syrian and Chinese hamsters. Biochem Pharmacol 1992, 44(11): 2266-70.
102. Burgess, M.A., Bodey, G.P. Clotrimazole (Bay b 5097): In vitro and clinical pharmacological studies. Antimicrob Agents Chemother 1972, 2(6): 423-6.
103. Stevens, D.A. Ketoconazole metamorphosis. An antimicrobial becomes an endocrine drug. Arch Intern Med 1985, 145(5): 813-5.
104. Pont, A., Graybill, J.R., Craven, P.C., Galgiani, J.N., Dismukes, W.E., Reitz, R.E., Stevens, D.A. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984, 144(11): 2150-3.
105. García Rodríguez, L.A., Duque, A., Castellsague, J., Pérez-Gutthann, S., Stricker, B. H. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999, 48(6): 847-52.
106. Brass, C., Galgiani, J.N., Blaschke, T.F., Defelice, R., O'Reilly, R.A., Stevens, D.A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 1982, 21(1): 151-8.
107. Daneshmend, T.K., Warnock, D.W., Ene, M.D., Johnson, E.M., Potten, M.R., Richardson, M.D., Williamson, P.J. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984, 25(1): 1-3.
108. Dominguez, J., Kompatzki, A., Foradori, A., Norambuena, R. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003, 35(7): 2522-3.
109. Gandhi, B.V., Kale, S., Bhowmik, D.M., Jain, A.K. Concomitant administration of cyclosporine and ketoconazole in renal transplant patients. Transplant Proc 1992, 24(5): 1715.
110. Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., Harrel, L.M., Tobias, S., Shader, R.I., Wright, C.E. Interaction of triazolam and ketoconazole. Lancet 1995, 345(8943): 191.
111. Kotegawa, T., Laurijssens, B.E., Von Moltke, L.L. et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 2002, 302(3): 1228-37.
112. Olkkola, K.T., Backman, J.T., Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994, 55(5): 481-5.
113. Anaissie, E.J., Kontoyiannis, D.P., Huls, C. et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995, 172(2): 599-602.
114. Goodman, J.L., Winston, D.J., Greenfield, R.A. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326(13): 845-51.
115. Pelz, R.K., Hendrix, C.W., Swoboda, S.M., Diener-West, M., Merz, W.G., Hammond, J., Lipsett, P.A. Double-blind placebo-controlled trial of fluconazole to prevent candidat infections in critically ill surgical patients. Ann Surg 2001, 233(4): 542-8.
116. Eggimann, P., Francioli, P., Bille, J. et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27(6): 1066-72.
117. De Waele, J.J., Vogelaers, D., Blot, S., Colardyn, F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003, 37(2): 208-13.
118. Grewe, M., Tsiotos, G.G., Luque deLeon, E., Sarr, M.G. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999, 188(4): 408-14.
119. Benedetti, E., Gruessner, A.C., Troppmann, C., Papalois, B.E., Sutherland, D.E., Dunn, D.L., Gruessner, R.W. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 1996, 183(4): 307-16.
120. Calandra, T., Marchetti, O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004, 39 Suppl 4: S185-92.
121. Rodríguez-Tudela, J.L., Almirante, B., Rodríguez-Pardo, D. et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007, 51(10): 3599-604.
122. Bennett, J.E., Izumikawa, K., Marr, K.A. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004, 48(5): 1773-7.
123. Hitchcock, C.A., Pye, G.W., Troke, P.P., Johnson, EM., Warnock, D.W. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993, 37(9): 1962-5.
124. Parkinson, T., Falconer, D.J., Hitchcock, C.A. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995, 39(8): 1696-9.
125. Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., Fadda, G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005, 49(2): 668-79.
126. Sanglard, D., Ischer, F., Monod, M., Bille, J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996, 40(10): 2300-5.
127. White, T.C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother 1997, 41(7): 1488-94.
128. Sanglard, D., Odds, F.C. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2(2): 73-85.
129. Perea, S., López-Ribot, J.L., Kirkpatrick, W. R. et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001, 45(10): 2676-84.
130. Goldman, G.H., da Silva Ferreira, M.E., dos Reis Marques, E. et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004, 50(1): 25-32.
131. Ribeiro, M.A., Paula, C.R., John, R., Perfect, J.R., Cox, G.M. Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. Med Mycol 2005, 43(7): 647-50.
132. Denes, E., Pichon, N., Debette-Gratien, M., Bouteille, B., Gaulier, J.M. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin Infect Dis 2004, 39(4): 603-4.
133. Hariprasad, S.M., Mieler, W.F., Holz, E.R., Gao, H., Kim, J.E., Chi, J., Prince, R.A. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004, 122(1): 42-7.
134. Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S.M., Ambrose, P.G., Andes, D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50(4): 1570-2.
135. Trifilio, S., Pennick, G., Pi, J. et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109(8): 1532-5.
136. Kullberg, B.J., Sobel, J.D., Ruhnke, M. et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 2005, 366(9495): 1435-42.
137. Cuenca-Estrella, M., Díaz-Guerra, T.M., Mellado, E., Monzón, A., Rodríguez-Tudela, J.L Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 1999, 18(6): 432-5.
138. Fukuoka, T., Johnston, D.A., Winslow, C.A., de Groot, M.J., Burt, C., Hitchcock, C.A., Filler, S.G. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003, 47(4): 1213-9.
139. Johnson, L.B., Kauffman, C.A. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003, 36(5): 630-7.
140. Koul, A., Vitullo, J., Reyes, G., Ghannoum, M. Effects of voriconazole on Candida glabrata in vitro. J Antimicrob Chemother 1999, 44(1): 109-12.
141. Pfaller, M.A., Diekema, D.J., Rex, J.H. et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006, 44(3): 819-26.
142. Perfect, J.R., Marr, K.A., Walsh, T.J. et al. Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36(9): 1122-31.
143. Graybill, J.R. Voriconazole for candidosis: an important addition? Lancet 2005, 366(9495): 1413-4.
144. Greenberg, R.N., Mullane, K., van Burik, J.A. et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50(1): 126-33.
145. van Burik, J.A., Hare, R.S., Solomon, H.R, Corrado, M.L., Kontoyiannis, D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42(7): e61-5.
146. Keating, G.M. Posaconazole. Drugs 2005, 65(11): 1553-67.
147. Pitisuttithum, P., Negroni, R., Graybill, J.R. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56(4): 745-55.
148. Skiest, D.J., Vazquez, J.A., Anstead, G.M. et al. Posaconazole for the treatment of azote-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007, 44(4): 607-14.
149. Denning, D.W. Echinocandin antifungal drugs. Lancet 2003, 362(9390): 1142-51.
150. Ernst, E.J., Klepser, M.E., Pfaller, M.A. Postantifungal effects of echinocandin, azote, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44(4): 1108-11.
151. Debono, M., Gordee, R.S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994, 48: 471-97.
152. Deresinski, S.C., Stevens, D.A. Caspofungin. Clin Infect Dis 2003, 36(11): 1445-57.
153. Vazquez, J.A., Sobel, J.D. Anidulafungin: A novel echinocandin. Clin Infect Dis 2006, 43(2): 215-22.
154. Theuretzbacher. U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004, 23(11): 805-12.
155. Eschenauer, G., Depestel, D.D., Carver, P.L. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007, 3(1): 71-97.
156. Chandrasekar, RH., Sobel, J.D. Micafungin: A new echinocandin. Clin Infect Dis 2006, 42(8): 1171-8.
157. Vazquez, J.A. Anidulafungin: A new echinocandin with a novel profile. Clin Ther 2005, 27(6): 657-73.
158. Letscher-Bru, V., Herbrecht, R. Caspofungin: The first representative of a new antifungal class. J Antimicrob Chemother 2003, 51(3): 513-21.
159. Paderu, R, Garcia-Effron, G., Balashov, S., Delmas, G., Park, S., Perlin, D.S. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007, 51 (6): 2253-6.
160. Wiederhold, N.P., Najvar, L.K., Bocanegra, R., Molina, D., Olivo, M., Graybill, J.R. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007, 51(5): 1616-20.
161. Pappas, P.G., Rotstein, C.M., Betts, R.F. et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45(7): 883-93.
162. Douglas, C.M., D'Ippolito, U.A., Shei, G.J. et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997, 41(11): 2471-9.
163. Douglas, C.M., Marrinan, J.A., Li, W., Kurtz, M.B. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol 1994, 176(18): 5686-96.
164. Hernandez, S., López-Ribot, J.L., Najvar, L.K., McCarthy, D.I., Bocanegra, R., Graybill, J.R. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004, 48(4): 1382-3.
165. Park, S., Kelly, R., Kahn, J.N. et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005, 49(8): 3264-73.
166. Melo, A.S., Colombo, A.L., Arthington-Skaggs, B.A. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007, 51(9): 3081-8.
167. Clemons, K.V., Espiritu, M., Parmar, R., Stevens, D.A. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006, 50(4): 1293-7.
168. Hiemenz, J., Cagnoni, P., Simpson, D., Devine, S., Chao, M. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant recipients. 39th Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 26-29, San Francisco) 1999, Abst J1648.
169. Hiemenz, J., Cagnoni, P., Simpson, D. et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005, 49(4): 1331-6.
170. Marr, K.A., Hachem, R., Papanicolaou, G. et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004, 6(3): 110-6.
171. Mora-Duarte, J., Betts, R., Rotstein, C. et al.; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347(25): 2020-9.
172. Reboli, A.C., Rotstein, C., Pappas, P.G. et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356(24): 2472-82.
173. Kuse, E.R., Chetchotisakd, P., da Cunha, C.A. et al. ; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007, 369(9572): 1519-27.
174. Pfaller, M.A., Boyken, L., Mollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46(1): 150-6.
175. Moudgal, V., Little, T., Boikov, D., Vazquez, J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005, 49(2): 767-9.
176. Odabasi, Z., Paetznick, V., Goldstein, B.P., Rex, J.H., Ostrosky-Zeichner, L. Disk diffusion-based methods for deter mining Candida parapsilosis susceptibility to anidulafungin. Antimicrob Agents Chemother 2003, 47(9): 3018-20.
177. Hawser, S.P., Douglas, L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995, 39(9): 2128-31.
178. Apisarnthanarak, A., Little, J.R., Tebas, P. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002, 346(22): 1745-7; author reply 1745-7.
179. Walsh, T.J., Goodman, J.L., Pappas, P. et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45(12): 3487-96.
180. Cornely, O.A., Maertens, J., Bresnik, M. et al.; AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44(10): 1289-97.
181. Cruciani, M., Serpelloni, G. Management of Candida infections in the adult intensive care unit. Expert Opin Pharmacother 2008, 9(2): 175-91.
182. Spellberg, B.J., Filler, S.G., Edwards, J.E. Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006, 42(2): 244-51.
183. Flückiger, U., Marchetti, O., Bille, J. et al.; Fungal Infection Network of Switzerland (FUNGINOS). Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006, 136(29-30): 447-63.
184. Safdar, A., van Rhee, F., Henslee-Downey, J.P., Singhal, S., Mehta, J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: No adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001, 28(9): 873-8.
185. Clancy, C.J., Staley, B., Nguyen, M.H. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother 2006, 50(10): 3496-8.
186. Walsh, T.J., Donowitz, G.R., DePauw, B. E. Caspofungin versus liposomalamphotericin B for empirical therapy (author reply). N Engl J Med 2005, 352(4): 410-4; author reply 410-4.
187. Tortorano, A.M., Biraghi, E., Astolfi, A. et al.; FIMUA Candidemia Study Group. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: Report from one Italian region. J Hosp Infect 2002, 51(4): 297-304.
188. Almirante, B., Rodriguez, D., Park, B.J. et al.; Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43(4): 1829-35.
189. Tortorano, A.M., Peman, J., Bernhardt, H. et al.; ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23(4): 317-22.
190. Herbrecht, R., Flueckiger, U., Gachot, B., Ribaud, P., Thiebaut, A., Cordonnier, C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007, 5(2): 49-59.
191. Gavaldà, J., Ruiz, I.; Grupo de Estudio de Micologia Médica (MICOMED); Grupo de Estudio de Infección en el Transplante (GESITRA); Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). [Guidelines for the treatment of infection due to Aspergillus spp]. Enferm Infecc Microbiol Clin 2003, 21(10): 571-8.
192. Rex, J.H., Pappas, P.G., Karchmer, A.W. et al.; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36(10): 1221-8.
193. Böhme, A., Ruhnke, M., Buchheidt, D. et al.; Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003, 82 Suppl 2: S133-40.
194. Smith, P.B., Steinbach, W.J., Benjamin, D.K. Jr. Neonatal candidiasis. Infect Dis Clin North Am 2005, 19(3): 603-15.
195. Saiman, L., Ludington, E., Pfaller, M. et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000, 19(4): 319-24.
196. Zaoutis, T., Walsh, T.J. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis 2007, 20(6): 592-7.
197. Bliss, J.M., Wellington, M., Gigliotti, F. Antifungal pharmacotherapy for neonatal candidiasis. Semin Perinatol 2003, 27(5): 365-74.
198. Almirante, B., Rodríguez, D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 2007, 9(5): 311-21.
199. Juster-Reicher, A., Flidel-Rimon, O., Amitay, M., Even-Tov, S., Shinwell, E., Leibovitz, E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003, 22(10): 603-7.
200. Scarcella, A., Pasquariello, M.B., Giugliano, B., Vendemmia, M., de Lucia, A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998, 17(2): 146-8.
201. Linder, N., Klinger, G., Shalit, I. et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003, 52(4): 663-7.
202. Adler-Shohet, F., Waskin, H., Lieberman, J.M. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001, 84(2): F131-3.
203. Walsh, T.J., Seibel, N.L., Arndt, C. et al. Amphotericin B lipid complex in pediatrie patients with invasive fungal infections. Pediatr Infect Dis J 1999, 18(8): 702-8.
204. López Sastre, J.B., Goto Cotallo, G.D., Fernández Colomer, B.; Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003, 20(3): 153-63.
205. Driessen, M., Ellis, J.B., Cooper, P.A. et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr Infect Dis J 1996, 15(12): 1107-12.
206. Fasano, C., O'Keeffe, J., Gibbs, D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994, 13(4): 351-4.
207. Wainer, S., Cooper, P.A., Gouws, H., Akierman, A. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997, 16(8): 763-7.
208. Odio, C.M., Araya, R., Pinto, L.E. et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004, 23(12): 1093-7.
209. Natarajan, G., Lulic-Botica, M., Rongkavilit, C., Pappas, A., Bedard, M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25(12): 770-7.
210. Manzar, S., Kamat, M., Pyati, S. Caspofungin for refractory candidemia in neonates. Pediatr Infect Dis J 2006, 25(3): 282-3.
211. 211.Walsh, T.J., Adamson, P.C., Seibel, N.L. et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49(11): 4536-45.
212. Queiroz-Telles, F., Berezin, E., Leverger, G. et al Micafungin versus liposomal amphotericin B (AmBisomeR) for paediatric patients with invasive candidiais: substudy of a randomized double-blind trial. Ped Infect Dis J 2008, in press.
213. Rex, J.H., Sobel, J.D. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32(8): 1191-200.
214. Shorr, A.F., Chung, K., Jackson, W.L, Waterman, P.E., Kollef, M.H. Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 2005, 33(9): 1928-35.
215. Playford, E.G., Webster, A.C., Sorrell, T.C., Craig, U.C. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and metaanalysis of randomizedclinical trials. Antimicrob Chemother 2006, 57(4): 628-38.
216. Paya, C.V. Prevention of fungal infection in transplantation. Transpl Infect Dis 2002, 4(Suppl 3): 46-51.
217. Singh, N., Wagener, M.M., Marino, I.R., Gayowski, T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002, 73(1): 63-7.
218. Fung, J.J. Fungal infection in liver transplantation. Transpl Infect Dis 2002, 4 Suppl 3: 18-23.
219. Winston, D.J., Pakrasi, A., Busuttil, R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131(10): 729-37.
220. Paya, C.V. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993, 16(5): 677-88.
221. Kicklighter, S.D., Springer, S.C., Cox, T., Hulsey, T.C., Turner, R.B. Fluconazole for prophylaxis against Candidal rectal colonization in the very low birth weight infant. Pediatrics 2001, 107(2): 293-8.
222. Kaufman, D., Boyle, R., Hazen, K.C., Patrie, J.T., Robinson, M., Donowitz, L. G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345(23): 1660-6.
223. Manzoni, P., Stolfi, I., Pugni, L. et al.; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356(24): 2483-95.
224. Burwell, L.A., Kaufman, D., Blakely, J., Stoll, B.J., Fridkin, S.K. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics 2006, 118(4): e1019-26.
225. Santolaya, M.E., Rabagliati, R., Bidart, T. et al.; Sociedad Chilena de Infectologia; Sociedad Chilena de Hematología. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005, 22 Suppl 2: S79-113.
226. Cornely, O.A., Maertens, J., Winston, D.J. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4): 348-59.
227. Ullmann, A.J., Lipton, J.H., Vesole, D.H. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356(4): 335-47.